Franklin Resources
CTMX icon

Franklin Resources’s CytomX Therapeutics CTMX Stock Holding History

Franklin Resources’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,769,230
Closed -$13.1M – 3161
2025
Q2 		$13.1M Buy
+5,769,230
New +$9.3M ﹤0.01% 1049
2024
Q1 		– Sell
-26,838
Closed -$41.6K – 2894
2023
Q4 		$41.6K Hold
26,838
– – ﹤0.01% 2533
2023
Q3 		$34.6K Sell
26,838
-7,246
-21% -$11.4K ﹤0.01% 2559
2023
Q2 		$58.6K Hold
34,084
– – ﹤0.01% 2600
2023
Q1 		$51.5K Hold
34,084
– – ﹤0.01% 2182
2022
Q4 		$54.5K Hold
34,084
– – ﹤0.01% 2206
2022
Q3 		$49K Hold
34,084
– – ﹤0.01% 2201
2022
Q2 		$62K Sell
34,084
-16,595
-33% -$31.8K ﹤0.01% 2212
2022
Q1 		$135K Hold
50,679
– – ﹤0.01% 2242
2021
Q4 		$219K Sell
50,679
-121
-0.2% -$709 ﹤0.01% 2204
2021
Q3 		$259K Buy
+50,800
New +$272K ﹤0.01% 2135
2018
Q4 		– Sell
-333,576
Closed -$6.17M – 1484
2018
Q3 		$6.17M Hold
333,576
– – ﹤0.01% 1018
2018
Q2 		$7.63M Buy
333,576
+76
+0% +$1.94K ﹤0.01% 972
2018
Q1 		$9.49M Hold
333,500
– – ﹤0.01% 930
2017
Q4 		$7.04M Hold
333,500
– – ﹤0.01% 1015
2017
Q3 		$6.06M Hold
333,500
– – ﹤0.01% 1034
2017
Q2 		$5.17M Hold
333,500
– – ﹤0.01% 1077
2017
Q1 		$5.76M Hold
333,500
– – ﹤0.01% 1081
2016
Q4 		$3.67M Hold
333,500
– – ﹤0.01% 1137
2016
Q3 		$5.23M Hold
333,500
– – ﹤0.01% 1099
2016
Q2 		$3.41M Buy
333,500
+33,500
+11% +$382K ﹤0.01% 1166
2016
Q1 		$3.87M Hold
300,000
– – ﹤0.01% 1147
2015
Q4 		$6.26M Buy
+300,000
New +$4.75M ﹤0.01% 1092

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Franklin Resources's CTMX Position: Q3 2025 in Review

Franklin Resources sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 5,769,230 shares — an estimated $13.1M sold.

Franklin Resources first reported a position in CTMX in Q4 2015 and held it in 23 quarters. The position peaked at $13.1M in Q2 2025. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

  • Franklin Resources reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Franklin Resources sold 5,769,230 CytomX Therapeutics shares in Q3 2025, an estimated $13.1M.
  • Franklin Resources first reported a position in CytomX Therapeutics in Q4 2015 and held it in 23 quarters.
  • Franklin Resources's CytomX Therapeutics position peaked at $13.1M in Q2 2025.
  • 103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.